(Sharecast News) - UK-based biotechnology company ReNeuron Group, which specialises in stem cell-derived exosome technologies, announced significant advancements in the field of exosome research on Monday.
The AIM-traded firm said it had successfully generated in vivo - within a living organism - data that demonstrated the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines.
That breakthrough could potentially pave the way for a more effective delivery of therapeutic payloads in various medical applications.
Having achieved the milestone, the company said it now planned to expand its research and development efforts, broadening its capabilities and focussing on the functional delivery of specific payloads.
"I am pleased to confirm that over the last six months we have generated comparative in vivo data demonstrating distinct organ and cellular targeting capabilities of our proprietary stem-cell derived exosomes, which differentiates our CustomEX platform from that of our competitors," said chief scientific officer Randolph Corteling.
Iain Ross, executive chairman, added that on the basis of the data, the company would now look to broaden its capabilities and, in liaison with partners and collaborators, focus on the functional delivery of specific payloads.
"We look forward to updating shareholders in due course."
At 0935 BST, shares in ReNeuron Group were down 2.63% at 9.01p.
Reporting by Josh White for Sharecast.com.
Reneuron (RENE)